SYRS — Syros Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$17.19m
- $9.94m
Brief: Syros Pharmaceuticals Q4 EPS USD -2.18
Brief: Syros Announces Completion Of Enrollment Necessary For Primary Endpoint Analysis In Phase 3 Trial
Syros Pharmaceuticals Inc expected to post a loss of $1.14 a share - Earnings Preview
Syros Pharmaceuticals Inc expected to post a loss of $1.14 a share - Earnings Preview
Brief: Syros Highlights Anticipated 2024 Milestones To Deliver On The Value Of Tamibarotene
Brief: Point72 Asset Management Reports 5.7% Passive Stake In Syros Pharmaceuticals As Of December 21, 2023
Brief: Syros Announces Pricing of $45 Mln Underwritten Offering of Common Stock and Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
Syros Pharma rises on positive cancer therapy data
Brief: Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Brief: Syros Pharmaceuticals Q3 EPS USD -1.43
U.S. RESEARCH ROUNDUP-Fiverr International, Ncino, Wingstop
Brief: Syros Pharmaceuticals On Aug 9, Got Notice From Incyte To Terminate Deal Dated Jan 8,2018
Syros Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Syros Reports Second Quarter 2023 Financial Results
Syros Pharmaceuticals Inc expected to post a loss of $1.13 a share - Earnings Preview
Pfizer to end license deal with Syros for blood disorder therapies
Syros Pharmaceuticals drops as Pfizer terminates license deal